MSD Signs an Exclusive License and Research Agreement with Themis Bioscience to Develop Vaccine Therapies

Shots:

• MSD enters into a research collaboration and exclusive license agreement for the discovery and development of undisclosed vaccine candidates utilizing Themis’ measles virus vector-based platform
• Themis to receive ~200M development and commercial milestones and royalties on approved products from the agreement. MSD to provide research funding and make an equity investment in Themis
• Themis licenses its measles virus vector-based platform from the Pasteur Institute in Paris, incorporating large recombinant genes coding for selected antigens into its genome

Click here to­ read full press release/ article | Ref: Themis Bioscience | Image: Guide-Post Solutions